摘要
目的探讨环磷酰胺联合激素治疗特发性膜性肾病患者的临床疗效及安全性。方法选取2016年3月至2018年12月朝阳市中心医院收治的98例特发性膜性肾病患者作为研究对象,依据用药方案不同分为对照组45例单用激素治疗的患者,观察组53例激素联合环磷酰胺治疗的患者,比较两组患者治疗前后肾功能、炎症介质及临床效果。结果治疗后两组患者肾功能各指标及白细胞介素-18(IL-18)、细胞间黏附分子-1(ICAM-1)水平低于治疗前,且观察组患者各指标低于对照组,差异有统计学意义(P<0.05);观察组治疗有效率为73.3%(33/45),显著高于对照组的73.3%(33/45),差异有统计学意义(P<0.05)。结论环磷酰胺联合激素治疗特发性膜性肾病临床疗效显著,可有效改善患者肾功能,减轻炎症反应,减缓向终末期肾病进展,可作为该疾病的首选治疗方式。
Objective To investigate the clinical efficacy and safety of cyclophosphamide combined with hormone for the treatment of membranous nephropathy.Methods From March 2016 to December 2018,98 patients with membranous nephropathy were selected in Chaoyang Central Hospital.According to the different drug methods,they were divided into a control group with 45 patients treated with hormone alone and observation group with 53 patients treated with hormone combined with cyclophosphamide.The levels of renal function,inflammatory mediators and clinical effects were compared between the 2 groups before and after treatment.Results After the treatment,the indexes of renal function,Interleukin-18(IL-18),intercellular adhesion molecule-1(ICAM-1)levels in the 2 groups were significantly lower than those before treatment,the difference was statistically significant(P<0.05);In the observation group,the treatment effective rate in the observation group was 73.3%(33/45),which was significantly higher than that of the control group 73.3%(33/45),and the difference was statistically significant(P<0.05).Conclusion Cyclophosphamide combined with hormone can significantly reduce a significant clinical effects in treating idiopathic membranous nephropathy,which can effectively improve patients’renal function,reduce inflammation,and slow the progression to end-stage renal disease.It can be the preferred treatment for this disease.
作者
董航
DONG Hang(Nephrology Department,Chaoyang Central Hospital,Chaoyang 122000,China)
出处
《中国药物经济学》
2020年第3期32-35,共4页
China Journal of Pharmaceutical Economics
关键词
环磷酰胺
激素
特发性膜性肾病
肾功能
临床疗效
Cyclophosphamide
Hormone
Membranous nephropathy
Renal function
Clinical efficacy
